BPC-157 + TB-500 + KPV - Coremend / FLOW / Repair-type

1 Identity

Fixed-ratio three-component article: three synthetic linear peptides, co-lyophilized. A formulation, not a substance. This is the KLOW composition without the copper complex, which changes the analytical treatment fundamentally: with no Cu(II) present, qNMR returns as an available net-content method and ICP-MS loses its orthogonal role.

Contains BPC-157 + TB-500 + KPV

Sequence

Per component, cross-referenced. BPC-157: GEPPPGKPADDAGLV, free acid. Full-length thymosin beta-4: Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-OH, Met6 the single oxidation-labile residue and Phe12 the only aromatic residue in the whole article. KPV: H-Lys-Pro-Val-OH, free acid specified, the C-terminal amide being a different molecule and a specified impurity.

Molecular formula

Per component. BPC-157 C62H98N16O22. Thymosin beta-4 C212H350N56O78S. KPV C16H30N4O4 as the free acid; salt forms move gross fill weight materially — mono-acetate C18H34N4O6, bis-trifluoroacetate C20H32F6N4O8, of which 40.0 percent of gross weight is counter-ion — so the salt is stated per component. No combined formula is written. Total nominal fill is stated alongside the per-component fills.

Average mass

Per component: BPC-157 1,419.556 Da; thymosin beta-4 4,963.506 Da; KPV 342.440 Da. At an observed 10 plus 10 plus 10 mg presentation, total nominal fill 30 mg: 7.044, 2.015 and 29.202 micromol — a 3.50 : 1.00 : 14.49 molar ratio out of a 1 : 1 : 1 mass ratio. A fourteen-fold molar spread from an equal-mass fill is the number that most often surprises on this article, and it is arithmetic rather than opinion.

Monoisotopic mass

Per component: BPC-157 1,418.7042 neutral, [M+H]+ 1,419.7115; thymosin beta-4 4,960.48632 neutral from a deconvoluted charge envelope, [M+4H]4+ 1,241.12886; KPV 342.22671 neutral, [M+H]+ 343.23399, with the C-terminal amide at 341.24269 sitting 0.98 Da away — a separation a nominal-mass instrument cannot resolve, so its output is not accepted for this component.

Salt / variant note

(1) the thymosin fork: 43-mer at 4,963.506 Da against the Tb4(17-23) heptapeptide at 889.018 Da under one market name. Substituting the fragment changes the deconvolution algebra, because the heptapeptide carries no alanine, no aspartate, no glycine and no proline. (2) the KPV fork: free acid 342.44 against C-terminal amide 341.46, both supplied as alpha-MSH(11-13) by different institutional houses; and KdPT, Lys-D-Pro-Thr, 344.41, a different sequence carrying a D-proline. (3) ratio: 10/10/10 mg is observed, other presentations circulate and none is standard. (4) Counter-ion per component, since a bis-trifluoroacetate KPV load is 40 percent counter-ion by gross weight.

2 Class & testing panel

Form

Fixed-ratio blend

Testing panel

P1 — panel definitionfor all three components, run per component rather than once on the mixture and never once on the vial. No metal, no lipid, no D-residue, no non-proteinogenic residue in any component. If a thymosin lot is supplied as recombinant material the article moves to P4 in full. Two method points are specific to this composition. First, BPC-157 has no unique residue at all here: KPV's lysine, proline and valine are each also in BPC-157, and BPC-157's alanine, aspartate, glutamate, glycine and leucine are each also in the 43-mer, so the method specifies the two-by-two valine and proline solve instead of a single marker residue. Second, with no copper present, qNMR is available and ICP-MS carries no orthogonal quantitation, so the method inversion used on the copper-bearing blends is not carried across to this article

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

Literature exists for each component, is graded and cited on that component's record and is cross-referenced from here. The KPV literature is entirely preclinical and analytical, and the human clinical material that circulates under the KPV name belongs to KdPT, a different molecule. None of the component literature is about this mixture, and no published study of this fixed three-component combination has been identified, which is a statement about the search.

4 Storage & specification

Storage

Co-lyophilized solid at -20 degrees C plus or minus 5 degrees C, desiccated with in-pack desiccant, protected from light, nitrogen headspace re-blanketed after subdivision, sealed vial equilibrated to room temperature before opening. The condition is the most restrictive of the three components' conditions, applied to the whole article. The nitrogen blanket is driven by Met6 in the thymosin component; the desiccant and the equilibration step are driven by KPV, on which moisture and temperature accelerate diketopiperazine formation, and by the hygroscopicity of all three solids. 2-8 degrees C is acceptable for transit only.

Shelf life

Provisional 24 months at -20 degrees C plus or minus 5 degrees C, taken as the shortest of the three component intervals and set on this company's own data rather than inherited from the component studies. The blend runs its own protocol with a mandatory 6-month interim pull assaying specifically for cyclo(Lys-Pro), free valine and methionine sulfoxide rather than for total impurities, and trending per-component content, the measured ratio, water content and any new peak above 0.10 percent.